TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00041171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypericum perforatum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypericum perforatum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study: NCT05412355

Intervention type: PROCEDURE
Intervention: ERAS protocol
Description: ERAS protocol is a series of procedures that enhance the recovery of surgical patients. Patients were grouped according to whether the procedure was attempted.

Intervention type: PROCEDURE
Intervention: ERAS protocol
Description: ERAS protocol is a series of procedures that enhance the recovery of surgical patients. Patients were grouped according to whether the procedure was attempted.
Study: NCT00041171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study: NCT05202366

Intervention type: DRUG
Intervention: CGB-400 Topical Gel
Description: CGB-400 Gel contains two main ingredients: geranic acid and choline. Geranic acid, a naturally occurring essential oil/terpenoid, is a key ingredient in lemon grass and is also found in other natural materials such as cardamom. The other main ingredient in CAGE is choline, which is an essential dietary component and found in foods as free choline and as several esterified forms such as phosphocholine and phosphatidylcholine.
Study: NCT06002035

Intervention type: DIETARY_SUPPLEMENT
Intervention: Binom Vitamin D drops
Description: Take 30 drops (relative to 1ml) once a day, directly into the mouth or with complementary foods added

Intervention type: DIETARY_SUPPLEMENT
Intervention: Binom Vitamin D drops
Description: Take 30 drops (relative to 1ml) once a day, directly into the mouth or with complementary foods added

Intervention type: DIETARY_SUPPLEMENT
Intervention: Binom Vitamin D drops
Description: Take 30 drops (relative to 1ml) once a day, directly into the mouth or with complementary foods added
Study: NCT05705323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (iCBT)
Description: This CBT is specifically adapted for individuals experiencing tinnitus
Study: NCT00041171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT05705323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered mindfulness-based tinnitus stress reduction (iMBTSR)
Description: This is a mindfulness-based intervention specifically adapted for individuals experiencing tinnitus
Study: NCT05689073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conversational AI system
Description: The conversational AI system based on LLM processes user queries with a sophisticated generation, decision, action, and safety framework to provide optimal feedback. The system has several key features. Firstly, it utilizes retrieval-augmented in-context learning to enhance responses generated by the LLM, sourcing information from trustworthy websites. Secondly, it includes Guardrail module that addresses potential harmful content in the LLM-generated responses by clarifying and validating the content before delivery. Furthermore, the AI system is equipped with Self-checking memory module that retains essential clinical characteristics across multi-turn dialogues, ensuring the continuity and consistency of its interactions with users. The educational content about vaccination was derived from the official website of World Health Organization (https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-what-is-vaccination).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Printed educational Brochure
Description: A printed brochure whose content about vaccination was derived from the official website of World Health Organization (https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-what-is-vaccination).
Study: NCT05381090

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Venous blood collection
Description: Participants will undergo venous blood collection following an overnight fast and 5, 60 and 180 minutes following food intake.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Venous blood collection
Description: Participants will undergo venous blood collection following an overnight fast and 5, 60 and 180 minutes following food intake.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Venous blood collection
Description: Participants will undergo venous blood collection following an overnight fast and 5, 60 and 180 minutes following food intake.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Venous blood collection
Description: Participants will undergo venous blood collection following an overnight fast and 5, 60 and 180 minutes following food intake.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Venous blood collection
Description: Participants will undergo venous blood collection following an overnight fast and 5, 60 and 180 minutes following food intake.
Study: NCT02497638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: One month run-in of 850 mg metformin once daily, followed by 850 mg twice daily of metformin until progression.
Study: NCT06313632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine injection
Description: Erector spinae plane block with bupivacaine (0.5%) 30 mL once

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: ESP with matching saline placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitored Anesthesia Care
Description: Standard monitored anesthesia care

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Monitored Anesthesia Care
Description: Standard monitored anesthesia care
Study: NCT05481346

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multidomain training
Description: The training program has a duration of 18 weeks with 2 training sessions per week. The training will have a gradual progression of intensity. One day they train two blocks of strength and one block of cognitive exercises and on the second day, they train one block of power, one block of strength+cognitive and one block of aerobic training.~All sessions are 60 minutes long (10 minutes of warm-up, 40 minutes of training and 10 minutes of cool-down). Classes are in small groups of no more than 8 members.
Study: NCT02497638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 20 mg once daily until progression.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (corresponding to metformin)
Description: One month of one placebo tablet (corresponding to metformin) once daily, followed by one placebo tablet twice daily until progression.
Study: NCT04766385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7791
Description: oral administration
Study: NCT04962607

Intervention type: OTHER
Intervention: Neo-Putty® as dressing agents in pulpotomized primary molars
Description: Following removal of the coronal pulp with a round bur and hemostasis, the pulp stumps in the study group will be covered with Neo-Putty ® according to the manufacturer's instructions. Neo-Putty will be placed in the prepared cavity, and then covered with Vitrebond® and with a reinforced Zinc Oxide-Eugenol (IRM, Bayer-Leverkussen, Germany).~In the control group, a cotton pellet moistened with full-strength FC will be placed for 5 minutes on the amputated pulp, after reaching hemostasis. The pulp stumps will be then covered by IRM

Intervention type: OTHER
Intervention: Neo-Putty® as dressing agents in pulpotomized primary molars
Description: Following removal of the coronal pulp with a round bur and hemostasis, the pulp stumps in the study group will be covered with Neo-Putty ® according to the manufacturer's instructions. Neo-Putty will be placed in the prepared cavity, and then covered with Vitrebond® and with a reinforced Zinc Oxide-Eugenol (IRM, Bayer-Leverkussen, Germany).~In the control group, a cotton pellet moistened with full-strength FC will be placed for 5 minutes on the amputated pulp, after reaching hemostasis. The pulp stumps will be then covered by IRM
Study: NCT02497638

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (corresponding to atorvastatin)
Description: One placebo tablet (corresponding to atorvastatin) once daily until progression.
Study: NCT05092984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 77 patients will be treated with spironolactone Mylan 25mg/day for the first 3 months of the study. Dosage adjustment can be performed according to the eGFR (estimated Glomerular Filtration Rate) concentration at baseline and the serum potassium variation.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation.
Study: NCT05445908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: SKB264 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: SKB264 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: SKB264 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: SKB264 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: SKB264 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL-A167
Description: KL-A167 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL-A167
Description: KL-A167 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL-A167
Description: KL-A167 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
Study: NCT06366542

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Rehabilitation Therapy (VRT)
Description: The VRT exercises were composed of gaze stabilization, head motion and postural stability exercises with static and dynamic balance exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation Therapy (VRT)
Description: The VRT exercises were composed of gaze stabilization, head motion and postural stability exercises with static and dynamic balance exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality exercises
Description: The VR exercises included watching theraputic videos using the virtual reality goggles with static and dynamic balance exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optokinetic Stimulation exercises
Description: Optokinetic Stimulation is a type of visual stimulation used to improve visual function and balance in patients with vestibular disorders.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optokinetic Stimulation exercises
Description: Optokinetic Stimulation is a type of visual stimulation used to improve visual function and balance in patients with vestibular disorders.
Study: NCT06375642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab, Surufatinib and HAIC
Study: NCT06107439

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Bood and urine sampling
Description: Bood and urine sampling
Study: NCT04943458

Intervention type: OTHER
Intervention: Monitoring of cerebral autoregulation
Description: Patients will be monitored for cerebral autoregulation using a Vittamed 505 monitor to identify the dynamics of the autoregulation index VRx (t). Intracranial pressure (ICP) will also be measured by non-invasive ultrasound using a robotic TCD device, Dolphin4D (Israel), which simultaneously records MCA blood flow in both hemispheres of the brain. APAs will be assessed using mathematical models.

Intervention type: OTHER
Intervention: Monitoring of cerebral autoregulation
Description: Patients will be monitored for cerebral autoregulation using a Vittamed 505 monitor to identify the dynamics of the autoregulation index VRx (t). Intracranial pressure (ICP) will also be measured by non-invasive ultrasound using a robotic TCD device, Dolphin4D (Israel), which simultaneously records MCA blood flow in both hemispheres of the brain. APAs will be assessed using mathematical models.

Intervention type: OTHER
Intervention: Monitoring of cerebral autoregulation
Description: Patients will be monitored for cerebral autoregulation using a Vittamed 505 monitor to identify the dynamics of the autoregulation index VRx (t). Intracranial pressure (ICP) will also be measured by non-invasive ultrasound using a robotic TCD device, Dolphin4D (Israel), which simultaneously records MCA blood flow in both hemispheres of the brain. APAs will be assessed using mathematical models.
Study: NCT06247228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Click2Move
Description: One year multicomponent intervention including a wearable, and a mobile phone application downloaded in the own mobile phone. Participants will have activity tracking and app provision, sedentary reminders, cooperative challenges, organisational support and motivational messages, educational material, self-monitoring, feedback provision, demonstration videos and strategies.
Study: NCT05429645

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: setting up of the pace maker
Description: Setting up of a pace maker using a 3-dimensional (3D) guidance technique
Study: NCT05092984

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 77 patients will be treated with placebo 25mg/day for the first 3 months. At inclusion, a second randomization is automatically performed in the placebo arm to determine patients receiving a dose adjustment during the study to keep the double-blind.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation.
Study: NCT06212661

Intervention type: DRUG
Intervention: Ubrogepant
Description: Ubrogepant (Ubrelvy™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.

Intervention type: DRUG
Intervention: Rimegepant
Description: Rimegepant (Nurtec®), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.

Intervention type: DRUG
Intervention: Atogepant
Description: Atogepant (Qulipta™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.

Intervention type: DRUG
Intervention: Eptinezumab
Description: Eptinezumab (Vyepti®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.

Intervention type: DRUG
Intervention: Fremanezumab
Description: Fremanezumab (Ajovy®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.

Intervention type: DRUG
Intervention: Galcanezumab
Description: Galcanezumab (Emgality®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.

Intervention type: DRUG
Intervention: Erenumab
Description: Erenumab (Aimovig®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.

Intervention type: DRUG
Intervention: Botulinum toxin A
Description: Botolinum toxin A (Botox) injections into extracranial muscles, dosage at discretion of clinical provider, for treatment of migraines.
Study: NCT05380115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: weekly one on one video or telephone interviews with a study coach
Study: NCT05925335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transseptal Transcatheter Mitral valve-in-valve Replacement
Description: Transcatheter transfemoral mitral valve-in-valve replacement is an alternative surgery in patients with severe dysfunction of a degenerated mitral bioprosthesis and high surgical risk for repeat operation. The procedure is performed via femoral vein access. All procedures were carried out using intra-procedural TEE guidance to aid in transseptal puncture. After balloon septostomy, the bioprosthetic valve is introduced through the degenerative valve into the left ventricle and expanded in the mitral position during rapid ventricle pacing.
Study: NCT05850624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ice massage
Description: active phase when cervical dilatation was 6-8 cm. Ice will apply to the huko point (LI4 area) which is located on the dorsum of the hand, between the first and second metacarpal bones, between the thumb and the index finger for 20 minutes with an ice pack

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality animation
Description: cervical dilatation was 6-8 cm. Immediately after the second VAS application, the women will be asked about the video they wanted to watch of the sound of waves in the Ocean, rain falling or blooming trees with virtual reality glass. animation will show for a total of 20 min.
Study: NCT04730206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat
Description: 100 milligram tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets, identical in size and shape

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: 200 milligram tablets
Study: NCT04604197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Angiography and Clinical Follow up
Description: Angiography and Clinical Follow up

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Follow up
Description: Clinical Follow up
Study: NCT04758819

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comprehensive chromosomal Testing of Trophectoderm biopsies of Blastocysts (CTTEB)
Description: In vitro Fertilization by ICSI then embryo culture until Day 5/6; all blastocysts with morphological scores compatible with TE biopsy and vitrification will be submitted to Comprehensive chromosomal Testing of Trophectoderm biopsies of Blastocysts (CTTEB) and vitrified.
Study: NCT04368819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol 300 MG
Description: Allopurinol 300mg once daily for four weeks followed by allopurinol 300mg twice daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo 300mg once daily for four weeks followed by allopurinol 300mg twice daily for 12 weeks
Study: NCT04520932

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: RFA is performed under general anaesthesia, under high endoscopic echo-endoscopy (EEH), in left lateral decubitus position, using the StarMed generator from Taewong®.
Study: NCT05485298

Intervention type: OTHER
Intervention: visual analog scale
Description: Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.

Intervention type: OTHER
Intervention: visual analog scale
Description: Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
Study: NCT06216145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: formative evaluation
Description: Before the skills exam, the 'Self-Efficacy Survey in the Most Commonly Used Skill-Requiring Practices in Nursing' will be administered. Apart from the end-of-term skill exam, students will be given a different skill exam than the control group, in which they will not receive any grades. For applications requiring invasive interventions, a skill test will be administered in the laboratory.~For applications that do not require invasive intervention, a skill test will be administered in the clinical environment. At the end of the semester, students will be asked to fill out the 'Self-Efficacy Survey in Practices Requiring the Most Commonly Used Skills in Nursing'. At the end of the semester, students will be evaluated with 2 skill applications and skill exam scores to be selected by written exam and lottery method

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: formative evaluation
Description: Before the skills exam, the 'Self-Efficacy Survey in the Most Commonly Used Skill-Requiring Practices in Nursing' will be administered. Apart from the end-of-term skill exam, students will be given a different skill exam than the control group, in which they will not receive any grades. For applications requiring invasive interventions, a skill test will be administered in the laboratory.~For applications that do not require invasive intervention, a skill test will be administered in the clinical environment. At the end of the semester, students will be asked to fill out the 'Self-Efficacy Survey in Practices Requiring the Most Commonly Used Skills in Nursing'. At the end of the semester, students will be evaluated with 2 skill applications and skill exam scores to be selected by written exam and lottery method
Study: NCT06024057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX101
Description: LX101 (Containing recombinant human adeno-associated virus serotype 2, AAV2-RPE65 encoding human RPE65 gene).Specification: 0.2mL/bottle.Route of administration: subretinal injection, injection volume 0.3 mL/ eye
Study: NCT05847231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceived Stress, Mandala application
Description: Mandala